A gap approach for preventing stress in complex systems: managing natural hazard induced fiscal risks under a changing climate

Disasters associated with natural hazards as well as climate change are happening within complex socio-economic systems and desired system states, including sustainable development and resource management, are formulated on the global as well as regional and national levels. However, complex system approaches are yet only rudimentarily incorporated in related applications, and we discuss modeling as well as policy challenges focusing on fiscal risk. As an intermediate step we suggest a gap approach which we relate to fiscal stress levels a complex system may experience due to natural hazard events. We argue that in case of no gaps one can assume a no stress situation and therefore modeling of disruptions including cascading effects is less necessary. However, at the same time we also acknowledge that there is an urgent need to address corresponding challenges with complex system methods. Policy-wise our paper responds to concerns for real-world applications and can provide insights to support current discussions within the UNFCCC and Paris Agreement around both adaptation finance and the new funding arrangements for loss and damage from climate impacts established at COP27

VirtuWind: Virtual and Programmable Industrial Network Prototype Deployed in Operational Wind Park

With anticipated exponential growth of connected devices, future industrial networks require an open solutions architecture facilitated by standards and a strong ecosystem.VirtuWind aims to develop and demonstrate an SDN and NFV ecosystem, based on an open, modular and secure framework.A prototype of the framework for intra-domain and inter-domain scenarios will be showcased in real wind parks,as a representative use case of industrial networks. Validate the economic viability of the demonstrated solution is paramount for VirtuWind. This paper details this vision and explains steps forward

A Reactive Security Framework for Operational Wind Parks Using Service Function Chaining

The innovative application of 5G core technologies, namely Software Defined Networking (SDN) and Network Function Virtualization (NFV), can help reduce capital and operational expenditures in industrial networks. Nevertheless, SDN expands the attack surface of the communication infrastructure, thus necessitating the introduction of additional security mechanisms. A wind park is a good example of an industrial application relying on a network with strict performance, security, and reliability requirements, and was chosen as a representative example of industrial systems. This work highlights the benefit of leveraging the flexibility of SDN/NFV-enabled networks to deploy enhanced, reactive security mechanisms for the protection of the industrial network, via the use of Service Function Chaining. Moreover, a proof of concept implementation of the reactive security framework for an industrial-grade wind park network is presented. The framework is equipped with SDN and SCADA honeypots, modelled on (and deployable to) an actual, operating wind park, allowing continuous monitoring of the industrial network and detailed analysis of potential attacks, thus isolating attackers and enabling the assessment of their level of sophistication

Differential Proteome Analysis of Bone Marrow Mesenchymal Stem Cells from Adolescent Idiopathic Scoliosis Patients

Adolescent idiopathic scoliosis (AIS) is a complex three-dimensional deformity of the spine. The cause and pathogenesis of scoliosis and the accompanying generalized osteopenia remain unclear despite decades of extensive research. In this study, we utilized two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) coupled with mass spectrometry (MS) to analyze the differential proteome of bone marrow mesenchymal stem cells (BM-MSCs) from AIS patients. In total, 41 significantly altered protein spots were detected, of which 34 spots were identified by MALDI-TOF/TOF analysis and found to represent 25 distinct gene products. Among these proteins, five related to bone growth and development, including pyruvate kinase M2, annexin A2, heat shock 27 kDa protein, γ-actin, and β-actin, were found to be dysregulated and therefore selected for further validation by Western blot analysis. At the protein level, our results supported the previous hypothesis that decreased osteogenic differentiation ability of MSCs is one of the mechanisms leading to osteopenia in AIS. In summary, we analyzed the differential BM-MSCs proteome of AIS patients for the first time, which may help to elucidate the underlying molecular mechanisms of bone loss in AIS and also increase understanding of the etiology and pathogenesis of AIS

Anti-α-Internexin Autoantibody from Neuropsychiatric Lupus Induce Cognitive Damage via Inhibiting Axonal Elongation and Promote Neuron Apoptosis

Neuropsychiatric systemic lupus erythematosus (NPSLE) is a major complication for lupus patients, which often leads to cognitive disturbances and memory loss and contributes to a significant patient morbidity and mortality. The presence of anti-neuronal autoantibodies (aAbs) has been identified; as examples, anti-NMDA receptors and anti-Ribsomal P aAbs have been linked to certain pathophysiological features of NPSLE.In the current study, we used a proteomic approach to identify an intermediate neurofilament alpha-internexin (INA) as a pathogenetically relevant autoantigen in NPSLE. The significance of this finding was then validated in an expanded of a cohort of NPSLE patients (n = 67) and controls (n = 270) by demonstrating that high titers of anti-INA aAb was found in both the serum and cerebrospinal fluid (CSF) of ∼50% NPSLE. Subsequently, a murine model was developed by INA immunization that resulted in pronounced cognitive dysfunction that mimicked features of NPSLE. Histopathology in affected animals displayed cortical and hippocampal neuron apoptosis. In vitro studies further demonstrated that anti-INA Ab mediated neuronal damage via inhibiting axonal elongation and eventually driving the cells to apoptosis.Taken together, this study identified a novel anti-neurofilament aAb in NPSLE, and established a hitherto undescribed mechanism of aAb-mediated neuron damage that could have relevance to the pathophysiology of NPSLE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)